Compare OTEX & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTEX | APLS |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.2B |
| IPO Year | 1998 | 2015 |
| Metric | OTEX | APLS |
|---|---|---|
| Price | $23.42 | $40.86 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 21 |
| Target Price | ★ $37.50 | $32.71 |
| AVG Volume (30 Days) | 1.4M | ★ 8.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | ★ 1.24 | 0.20 |
| Revenue | ★ $2,815,241,000.00 | $1,003,782,000.00 |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $1.04 | $18.19 |
| P/E Ratio | ★ $18.65 | $204.23 |
| Revenue Growth | 22.88 | ★ 28.46 |
| 52 Week Low | $20.00 | $16.10 |
| 52 Week High | $39.90 | $40.88 |
| Indicator | OTEX | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 87.61 |
| Support Level | $22.44 | $18.53 |
| Resistance Level | $26.31 | N/A |
| Average True Range (ATR) | 0.91 | 0.20 |
| MACD | 0.27 | 0.69 |
| Stochastic Oscillator | 95.60 | 99.88 |
Open Text Corp is engaged in the design, development, marketing, and sale of Information Management software and solutions. Its software allows clients to archive, aggregate, retrieve, and search unstructured information (such as documents, e-mail, and presentations). Its platform and services provide secure and scalable solutions for enterprises, SMBs, governments, and consumers around the world. The company's solutions are marketed and delivered on the OpenText Cloud Platform, which is a comprehensive Information Management platform consisting of six business clouds; Content Cloud, Cybersecurity Cloud, Application Automation Cloud, Business Network Cloud, IT Operations Management Cloud, and Analytics Cloud. Geographically, it derives maximum revenue from the United States.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).